Tonix CCO discloses stock, 40,000-share option
Tonix Pharmaceuticals’ Chief Commercial Officer reported direct ownership of common stock and multiple option grants under the company’s 2020 Stock Incentive Plan.
Rhea-AI Filing Summary
Tonix Pharmaceuticals Holding Corp. (TNXP) reported the initial beneficial ownership of its Chief Commercial Officer, Thomas Englese, on a Form 3. He holds 694 shares of common stock directly and several stock options covering 500, 6,500, 12,480 and 40,000 underlying common shares, with exercise prices between $8.05 and $20.18 and expirations from September 9, 2034 to February 24, 2036. Footnotes state these options were granted under Tonix’s Amended and Restated 2020 Stock Incentive Plan and vest over three- or four-year schedules starting on each grant’s first anniversary.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Englese Thomas
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option F1 | -- | -- | -- |
| holding | Stock Option F2 | -- | -- | -- |
| holding | Stock Option F3 | -- | -- | -- |
| holding | Stock Option F4 | -- | -- | -- |
| holding | Common Stock, $0.001 par value per share | -- | -- | -- |
Holdings After Transaction:
Stock Option — 59,480 contracts (Direct);
Common Stock, $0.001 par value per share — 694 shares (Direct)
Footnotes (4)
- F1. The option was granted on September 9, 2024, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
- F2. The option was granted on February 25, 2025, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
- F3. The option was granted on May 13, 2025, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/4th on the first anniversary of issuance and 1/48th each month thereafter for 36 months.
- F4. The option was granted on February 24, 2026, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/4th on the first anniversary of issuance and 1/48th each month thereafter for 36 months.
Key Figures
Direct common shares held: 694 shares
Option underlying shares at $16.51: 500 shares
Option underlying shares at $8.05: 6,500 shares
+2 more
5 metrics
Direct common shares held
694 shares
Direct ownership of Tonix common stock as of September 4, 2026
Option underlying shares at $16.51
500 shares
Stock option exercisable at $16.51 expiring September 9, 2034
Option underlying shares at $8.05
6,500 shares
Stock option exercisable at $8.05 expiring February 25, 2035
Option underlying shares at $20.18
12,480 shares
Stock option exercisable at $20.18 expiring May 13, 2035
Option underlying shares at $14.29
40,000 shares
Stock option exercisable at $14.29 expiring February 24, 2036
Key Terms
Form 3, Stock Option, Amended and Restated 2020 Stock Incentive Plan, vesting
4 terms
Form 3 regulatory
"reported the initial beneficial ownership of its Chief Commercial Officer"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Stock Option financial
"He holds 694 shares of common stock directly and several stock options"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Amended and Restated 2020 Stock Incentive Plan financial
"granted on September 9, 2024, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan"
vesting financial
"The option vests 1/3rd on the first anniversary of issuance and 1/36th each month"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Tonix Pharmaceuticals (TNXP) disclose about Thomas Englese’s holdings on this Form 3?
Tonix disclosed that Chief Commercial Officer Thomas Englese directly owns 694 shares of common stock and holds several stock options over additional common shares, all reported as of September 4, 2026.
How many Tonix Pharmaceuticals (TNXP) stock options does Thomas Englese hold and at what exercise prices?
Thomas Englese holds options over 500 shares at $16.51, 6,500 shares at $8.05, 12,480 shares at $20.18, and 40,000 shares at $14.29, each exercisable for Tonix common stock.
When do Thomas Englese’s Tonix (TNXP) stock options expire?
The reported stock options expire on September 9, 2034, February 25, 2035, May 13, 2035, and February 24, 2036, respectively, as part of his equity compensation at Tonix Pharmaceuticals.
What are the vesting terms of Thomas Englese’s Tonix (TNXP) stock options?
For grants dated September 9, 2024 and February 25, 2025, options vest one-third on the first anniversary and one-thirty-sixth monthly for 24 months. For May 13, 2025 and February 24, 2026 grants, they vest one-fourth on the first anniversary and one-forty-eighth monthly for 36 months.
Under what plan were the Tonix (TNXP) options to Thomas Englese granted?
Footnotes state all reported options were granted under Tonix’s Amended and Restated 2020 Stock Incentive Plan, as amended, which governs the terms and vesting schedules of these equity awards.
AI-generated analysis. How Rhea-AI works. Not financial advice.
